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Background: Hypertension and tachycardia are common during ﬁber-optic bronchoscopy
(FOB), and this may lead to cardiac ischemia. The prophylactic addition of a beta-
adrenergic anatagonist might mask this response and prevent the deleterious cardiovas-
cular effects of FOB.
Methods: We performed a randomized double-blind placebo-controlled trial of labetalol
10mg iv given with midazolam-alfentanil sedation. We monitored heart rate (HR) and
systolic/diastolic blood pressure (SBP/DBP) throughout the bronchoscopy and calculated
the rate-pressure product (RPP ¼ (HR SBP)/100). One-hundred twenty patients were
enrolled.
Results: In the placebo group, there was no rise in HR, SBP, DBP or RPP, and there was no
difference between the placebo and labetalol groups. Adverse events during bronchoscopyElsevier Ltd. All rights reserved.
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ease; RPP: Rate-pressure product; SBP: Systolic blood pressure; SpO2: Oxygen saturation; VAS: Visual
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bronchoscopy, there was a trend towards lower SBP (p ¼ 0.06).
Conclusions: Patients undergoing FOB under adequate midazolam-alfentanil sedation do
not develop excessive sympathetic drive that may lead to cardiac stress. The addition of
labetalol did not confer additional beneﬁt or risk to the patients. (ClinicalTrials.gov
number, NCT00394537).
& 2008 Elsevier Ltd. All rights reserved.Introduction
Fiber-optic bronchscopy (FOB) is an essential diagnostic and
therapeutic modality in respiratory medicine. Conscious
sedation and topical anesthesia are required, since passing
the bronchoscope through the respiratory tract and larynx
leads to intense stress for the patient.1,2 The stress of
airway irritation and/or hypoxia during FOB causes release
of catecholamines, hence tachycardia, vasoconstriction and
the possibility of myocardial stress in some patients.3,4
Electrocardiographic evidence of myocardial ischemia has
been observed during FOB at rates of between 17–21%.4,5
Similar reactions occur during direct laryngoscopy at
the induction of anesthesia and endotracheal intubation,
although the stimulation is arguably more intense and of
shorter duration than during FOB.6 Premedication with beta-
blockers (usually esmolol given as a continuous infusion)
attenuates the sympathetic response to direct laryngo-
scopy.6Randomised
ocated to labetalol 10mg iv
(n=60)
ll patients received labetalol
Follow-up (n=60)
Analysed (n=60)
Assesse
eligibility (n
Figure 1 Participant ﬂoIn the present study, we evaluated the effects of the
short-acting beta blocker labetalol on the sympathetic
response to FOB in patients sedated with midazolam-
alfentanil. We hypothesized that labetalol given with the
premedication would prevent the tachycardia and hyperten-
sion associated with FOB.
Methods
Institutional ethical review board permission was obtained,
and all patients gave written informed consent.
Participants
All adult patients attending our day-admission unit for
FOB between 16 June 2006 and 31 March 2007 were
screened. Exclusion criteria were inability or refusal to
give informed consent, bronchoscopy through an artiﬁcialExcluded (n=69)
Artificial airway (n=18)
Bradycardia (n=16)
Hypotension (n=7)
Refused to participate (n=23)
Dilitiazem/Verapamil (n=3)
Use of propofol (n=2)
 (n=120)
Allocated to Placebo
(n=60)
One patient did not receive
study drug
Follow-up (n=60)
Analysed (n=60)
d for
=189)
w through the trial.
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Table 1 Baseline characteristics of the two groups.
Placebo Labetalol
n 60 60
Male 34 (56.7%) 33 (55%)
Age (mean7SD) 59.6714.5 57.4715.8
Medical History
IHD 9 10
Hypertension 25 25
Asthma 2 2
COPD 9 7
Anti-hypertensives
Beta blockers 16 19
ACE inhibitors 10 12
Diuretics 9 5
Alpha blockers 2 2
CCB 4 8
ARB 2 1
Indication for bronchoscopy
Lung Neoplasm 20 21
Lung Infection 6 9
Lung Transplant 13 16
Subglottic Stenosis 5 8
ILD 8 4
Brachytherapy catheter 4 1
Investigation of hemoptysis 2 1
Foreign body 2 0
Abbreviations are deﬁned elsewhere in the documentNo
statistically signiﬁcant differences were present between the
two groups at baseline.
B.D. Fox et al.980airway, intolerance or allergy to the study drug, bradycardia
(HRo60/min) or hypotension (SBP (systolic blood pressure)
o100) at screening, pregnancy, concomitant treatment
with diltiazem or verapamil and intention to use propofol
as the sedative agent for bronchoscopy. Based on existing
patient data, we estimated that 69 patients would need
to be enrolled to detect a 20mmHg difference in SBP with
90% power and type I error of 0.01. However, following
an interim analysis of data of 72 patients, with a near-
signiﬁcant difference between treatment groups, we
elected to enlarge the study to 120 patients.
Interventions
Participants randomized to active drug received labetalol
10mg iv (Trandate, GlaxoSmithKline, Uxbridge, United
Kingdom) given with the premedication prior to broncho-
scopy. Patients randomized to placebo received an equal
volume of saline 0.9% solution. Labetalol is combined beta
and alpha adrenergic antagonist that has rapid onset and
duration of action approximately 30min (appropriate for the
duration of a FOB examination). Labetalol reduces heart
rate (HR) and blood pressure and may cause bradycardia and
hypotension when given in excessive doses. Bronchospasm
has been reported in susceptible individuals.
Objectives
We recorded physiological parameters—HR, SBP, diastolic
blood pressure (DBP) and oxygen saturation (SpO2) at baseline
and then every 5min until recovery—deﬁned as 10min after
the completion of the bronchoscopy. We also calculated
the rate-pressure product (RPP) at each measurement
RPP ¼ (HR SBP)/100. RPP is an index of myocardial oxygen
demand and stress, with values over 200 correlating with
myocardial ischemia in susceptible individuals.7,8
Primary outcome measures were the HR, SBP, DBP and RPP
during and after FOB as compared to baseline values. In
addition, we recorded episodes of brady- or tachy-cardia
(HRo60 or4100, respectively); hyper- or hypo-tension (SBP
o100mmHg or 4180mmHg, respectively); and episodes of
RPP over 200.
Secondary outcome measures were hypoxemia, total
doses of sedative drugs received, and scores of patient
tolerance of the procedure. Hypoxemia was deﬁned as SpO2
less than 90% for more than 1min, or requiring an increase in
supplemental oxygen ﬂow delivered to the patient or
manipulation of the patient’s airway (for example perfor-
mance of a jaw-thrust maneuver or insertion of artiﬁcial
airway). The bronchoscopist evaluated the patient’s toler-
ance of the procedure using a 10 cm visual analogue scale
(VAS) immediately after ﬁnishing the procedure. After
recovery, patients rated the bronchoscopy for pain, recall
and satisfaction on a 10 cm VAS. VAS scales were 0–10 with
10 indicating the best possible outcome.
Randomization and blinding
Randomization to labetalol or placebo was done with a
computerized script. Patients were randomized in blocks of8, with sequential inclusion numbers. The computer-
generated ﬁle was passed un-opened to the nursing staff
of the day-admission unit of our institute. Upon study
enrollment the patient was assigned an inclusion number,
and the study drug was prepared outside the bronchoscopy
suite by a nurse uninvolved in the bronchoscopy. The syringe
was labelled with the patient’s inclusion number and then
passed to the bronchoscopist.
Bronchoscopy
All patients in our unit routinely receive supplemental
oxygen by nasal cannula and premedication with alfentanil
500mcg and midazolam as required. The study drug was
given with the premedication. Topical anesthesia was
achieved with lidocaine gel to the nose, and lidocaine 2%
solution given down the bronchoscope with the spray-as-
you-go technique. Additional midazolam/alfentanil was
given as required.
All other drug treatment during the bronchoscopy was
decided by the bronchoscopist. Hypertension during the
procedure was treated with sublingual glyceryl-trinitrate
spray. The procedure was classiﬁed as interventional if any
of the following were performed: insertion of brachytherapy
catheter, balloon airway dilatation, endobronchial laser,
foreign body retrieval or stent insertion. Otherwise the
procedure was classiﬁed as diagnostic.
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Analysis was by intention-to-treat. Data were analyzed using
SPSS software v14.0 (SPSS Inc. Chicago, IL) by a professional
statistician. Physiological parameters during FOB were
analyzed with repeated-measures ANOVA, using time as130
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Figure 2 Physiological response to bronchoscopy. Data are shown
panel-heart rate. Lower panel-rate pressure product.the within-subjects factor. Other continuous parameters
were analyzed with a Student’s t test, or the Mann–Whitney
U test as appropriate for the distribution of the data.
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Participant ﬂow
We screened 189 patients for inclusion in the study as
shown in Figure 1.
Baseline data
Baseline characteristics of the enrolled patients are shown
in Table 1.
Physiological changes
Trends in blood pressure, HR and RPP are shown in Figure 2
(data are abbreviated to the ﬁrst 20min of the procedure).
The data were analyzed with repeated-measures ANOVA. In
all parameters no signiﬁcant difference was seen between
the groups throughout the bronchoscopies (HR p ¼ 0.34, SBP
p ¼ 0.59, DBP p ¼ 0.77, and RPP p ¼ 0.86).
Adverse events
Predetermined adverse end-points are summarized in
Table 2. There was no difference between the two groups.
No patients required treatment for myocardial ischemia.Table 2 Data from bronchoscopy-there were no statis-
tically signiﬁcant differences between the groups in any
measure.
Placebo Labetalol
Adverse Events
RPP4200 4 2
Tachycardia 5 5
Bradycardia 4 4
Hypotension 4 3
Hypertension 9 9
Hypoxia 7 3
Bronchospasm 0 0
Bronchoscopy
Duration (mins) 22.5712.8 21.2711.8
Midazolam (mg) 6.873.6 6.573.4
Alfentanil (mcg) 6307290 6207310
Lidocaine (mg) 2407180 2457148
Required glyceryl-
trinitrate
7 3
Bronchoscopy perfomed
by attending physician
43 47
Diagnostic procedures 46 45
Interventional
procedures
14 15
Bronchoscopist VAS 7.0 (6.0–9.0) 7.0 (6.0–9.0)
Patient VAS-pain 10.0 (9.0–10.0) 10.0(6.0–10.0)
Patient VAS-recall 10.0(8.0–10.0) 10.0(5.8–10.0)
Patient VAS-satisfaction 10.0(9.0–10.0) 10.0(7.0–10.0)
Continuous parameters shown as mean7standard deviation.
VAS scores were analyzed with the Mann–Whitney U test are
reported as median (interquartile range).One patient in the labetalol arm who was undergoing FOB
for treatment of subglottic stenosis required intubation for
stridor and hypoxia. One patient in the placebo group
developed profound hypoxia and bradycardia during
bronchoscopy and required temoporary intubation and
ventilation. One patient in the placebo arm experienced
minor nasal bleeding that resolved spontaneously.
Patient tolerance of FOB
We did not ﬁnd any signiﬁcant differences between placebo
and labetalol in VAS by the bronchoscopist or the patients. In
addition, there was no signiﬁcant difference between the
two groups in the requirement for midazolam, alfentanil or
lidocaine (Table 2).
Sub-group analysis
We performed pre-planned subgroup analyses for patients
suffering from IHD or HTN, patients with subglottic stenosis,
patients receiving chronic beta-adrenergic antagonists, and
patients undergoing interventional bronchoscopy. In the
interventional bronchoscopy subgroup we observed a trend
towards lower SBP during the procedure (p ¼ 0.069).
Otherwise there was no difference between placebo and
labetalol in any subgroups.
Discussion
We performed a randomized double-blind study comparing
labetalol 10mg iv to placebo to control the sympathetic
response to FOB. We demonstrated that there was no
signiﬁcant difference between the labetalol and placebo
groups with regard to HR, blood pressures, RPP or adverse
events. We believe that our results are applicable to other
pulmonology departments, as all patients attending our unit
for bronchoscopy were eligible for enrollment. The trial had
adequate statistical power to detect a difference between
the two groups and the randomized-double-blind design of
this study and use of numerical and predeﬁned categorical
endpoints should have minimized bias in the data.
The surprising ﬁnding was that neither HR nor blood
pressure rose during FOB in the placebo group; rather all
parameters remained steady during FOB, followed by a fall
during the recovery period. This was contrary to previous
studies of the cardiovascular effects of FOB.3,9,10 The most
likely explanation for this ﬁnding is the sedation protocol. We
use midazolam for the sedative and anemestic effect, with
the addition of alfentanil for reducing cough and procedure
related pain. On average, our patients received 6.7mg
midazolam and 625mcg alfentanil (equivalent to approxi-
mately 12.5mg morphine), which is higher than other studies
employing similar benzodiazepine-opiate protocols.3 In some
studies cocaine was used as the local anaesthetic, and its
vasoconstricting action may have contributed to hypertension
or myocardial ischemia.4 Atropine has also been given in
many previous studies, which can lead to tachycardia.11
Overall, sedation techniques for FOB are variable across
different centers and countries, and this will undoubtedly
contribute to varying levels of sympathetic response to
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various sedative regimes, although fall short of recommend-
ing a particular protocol.1
In conclusion adequate midazolam-alfentanil sedation
blunts the sympathetic response to FOB in most patients,
and the prophylactic addition of intravenous labetalol has
no advantageous or deleterious effects on cardiovascular
stability. Apart from selected patients undergoing interven-
tional bronchoscopy, the routine addition of labetalol to this
type of sedative regime cannot be recommended.
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